Medline Inc. Class A Common Stock (MDLN)vsNyxoah (NYXH)
MDLN
Medline Inc. Class A Common Stock
$42.67
+1.52%
HEALTHCARE · Cap: $34.68B
NYXH
Nyxoah
$3.17
-0.63%
HEALTHCARE · Cap: $137.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 504103% more annual revenue ($28.43B vs $5.64M). MDLN leads profitability with a 4.1% profit margin vs 0.0%. MDLN earns a higher WallStSmart Score of 52/100 (C-).
MDLN
Buy52
out of 100
Grade: C-
NYXH
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.7%
Fair Value
$66.92
Current Price
$42.67
$24.25 discount
Intrinsic value data unavailable for NYXH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 55.8% year-over-year
Reasonable price relative to book value
Areas to Watch
Moderate valuation
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MDLN
Revenue growth of 14.8% demonstrates continued momentum.
Bull Case : NYXH
The strongest argument for NYXH centers on Revenue Growth, Price/Book. Revenue growth of 55.8% demonstrates continued momentum.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MDLN profiles as a value stock while NYXH is a hypergrowth play — different risk/reward profiles.
NYXH is growing revenue faster at 55.8% — sustainability is the question.
NYXH generates stronger free cash flow (-21M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MDLN scores higher overall (52/100 vs 29/100) and 14.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is a pioneering medical technology firm specializing in the treatment of obstructive sleep apnea (OSA) through its innovative Genio system, which employs a minimally invasive hypoglossal nerve stimulation technique. The company is dedicated to enhancing patient outcomes and quality of life for those affected by OSA, backed by a strong commitment to clinical validation and research excellence. Nyxoah's strategic emphasis on technology advancement, complemented by partnerships and extensive studies, not only positions it to address significant unmet needs in the sleep medicine market but also underscores its potential for sustainable growth and transformative contributions to the healthcare industry.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?